CORD-PICO  

CORD-19:85d7f47649ef43ff11b8d5196c98e4fdacd0f905 JSONTXT 9 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
p2_i0 0-31 Pharmacological denotes Angiotensin-converting enzyme 2
p2_i1 125-151 Pharmacological denotes Dale Hoyt and Daren Knoell
p1_all0 566-601 Intervention denotes Angiotensin-converting enzyme (ACE)
p1_all1 1982-2017 Intervention denotes Angiotensin-converting enzyme (ACE)
p1_all2 2209-2232 Outcome denotes Capillary blood vessels
p1_all3 2567-2593 Outcome denotes endothelial ACE expression
p2_o16 2567-2593 Physical denotes endothelial ACE expression
p2_o22 3759-3781 Physical denotes systemic ANG II levels
p1_all4 3759-3816 Outcome denotes systemic ANG II levels and impaired cardiac contractility
p2_o22 3795-3816 Physical denotes cardiac contractility
p1_all5 3845-3848 Intervention denotes ACE
p1_all6 4495-4505 Outcome denotes death rate
p2_o28 4495-4505 Mortality denotes death rate
p1_all7 5215-5219 Intervention denotes ACE2
p1_all8 5757-5871 Population denotes primary pulmonary hypertension, chronic obstructive pulmonary disease (COPD), high altitude or pulmonary embolism.
p2_o39 6518-6535 Physical denotes expression of ACE
p1_all9 6666-6687 Intervention denotes monocrotaline-treated
p2_i2 6666-6687 Pharmacological denotes monocrotaline-treated
p1_all10 6694-6775 Outcome denotes pulmonary hypertensive rats, both ANG II binding and the number of AT 1 receptors
p2_o40 6728-6742 Physical denotes ANG II binding
p2_o40 6751-6775 Physical denotes number of AT 1 receptors
p1_all11 6804-6818 Population denotes human patients
p1_all12 7323-7334 Intervention denotes ACE blocker
p2_i3 7323-7334 Pharmacological denotes ACE blocker
p1_all13 7443-7465 Outcome denotes pulmonary hypertension
p1_all14 7517-7538 Intervention denotes monocrotaline-treated
p2_i4 7517-7538 Pharmacological denotes monocrotaline-treated
p1_all15 7861-7915 Population denotes patients with pulmonary hypertension secondary to COPD
p2_i5 7969-7977 Pharmacological denotes losartan
p2_o45 8052-8120 Physical denotes pulmonary artery pressure, exercise capacity or breathlessness score
p1_all16 8052-8127 Outcome denotes pulmonary artery pressure, exercise capacity or breathlessness score [45] .
p1_all17 8247-8317 Population denotes hypoxic rats versus patients with COPD-related pulmonary hypertension.
p1_all18 8458-8561 Population denotes Etiologies include idiopathic pulmonary fibrosis, sarcoidosis, irradiation-induced pneumonitis or ARDS.
p2_o51 8716-8784 Physical denotes endothelial and epithelial cell injury, influx of inflammatory cells
p1_all19 9360-9372 Intervention denotes angiotensin-
p2_i6 9360-9372 Pharmacological denotes angiotensin-
p1_all20 9571-9594 Outcome denotes ANG II immunoreactivity
p2_o58 9571-9594 Physical denotes ANG II immunoreactivity
p2_i7 10608-10622 Pharmacological denotes ACE inhibitors
p2_o65 10699-10737 Physical denotes serum concentrations of ACE inhibitors
p1_all21 11763-11785 Outcome denotes D/D genotype frequency
p2_o70 11763-11785 Physical denotes D/D genotype frequency
p1_all22 11876-11890 Outcome denotes ACE D/D allele
p1_all23 11925-11934 Outcome denotes mortality
p2_o71 11925-11934 Mortality denotes mortality
p1_all24 12055-12068 Outcome denotes survival rate
p2_o76 12600-12621 Physical denotes vascular permeability
p1_all25 12600-12696 Outcome denotes vascular permeability, increased lung edema, neutrophil accumulation and worsened lung function.
p2_o76 12633-12668 Physical denotes lung edema, neutrophil accumulation
p1_all26 12779-12803 Intervention denotes recombinant ACE2 protein
p1_all27 12817-12846 Outcome denotes symptoms of acute lung injury
p2_o79 12985-13021 Physical denotes negative regulation of ANG II levels
p2_i8 13640-13654 Pharmacological denotes ACE inhibitors
p2_i9 13714-13723 Pharmacological denotes bleomycin
p1_all28 13714-13738 Intervention denotes bleomycin or irradiation
p1_all29 14485-14497 Outcome denotes Virus titers
p2_o88 14485-14497 Physical denotes Virus titers
p1_all30 14655-14669 Outcome denotes lung histology
p1_all31 14894-14898 Intervention denotes ACE2
p1_all32 14977-14985 Intervention denotes SARS-CoV
p2_i10 14977-14985 Pharmacological denotes SARS-CoV
p2_i11 15904-15912 Pharmacological denotes SARS-CoV
p1_all33 15920-15958 Outcome denotes markedly downregulated ACE2 expression
p1_all34 16001-16031 Intervention denotes recombinant SARS-spike protein
p2_i12 16001-16031 Pharmacological denotes recombinant SARS-spike protein
p2_i13 16143-16160 Pharmacological denotes SARS-CoV-infected
p1_all35 16387-16408 Outcome denotes ANG II peptide levels
p2_o97 16387-16408 Physical denotes ANG II peptide levels
p1_all36 16432-16454 Outcome denotes worsened ARDS symptoms
p2_o97 16432-16454 Physical denotes worsened ARDS symptoms
p1_all37 16564-16577 Outcome denotes ARDS symptoms
p2_o98 16564-16577 Physical denotes ARDS symptoms
p2_i14 17080-17094 Pharmacological denotes ACE inhibitors
p1_all38 17227-17241 Intervention denotes ACE inhibitors
p2_i15 17227-17241 Pharmacological denotes ACE inhibitors
p1_all39 17784-17809 Population denotes Japanese elderly patients
p2_o106 17819-17828 Mortality denotes mortality
p1_all40 18581-18622 Population denotes particular ACE2, 274 Respiratory Figure 2
p1_all41 18733-18828 Outcome denotes SARS-CoV infections, acid aspiration, pneumonias or sepsis, the generation of ANG II from ANG I
p2_o112 18797-18828 Physical denotes generation of ANG II from ANG I